Dr. Collins-Burow received her B.S. in Chemistry in 1994 from the University of Southern Mississippi. She completed her Ph.D. research in 1998 at Tulane University from the Interdisciplinary Graduate Program in Molecular and Cellular Biology. Dr. Collins-Burow went on to Medical School at Tulane University where she matriculated in 2002. Dr. Collins-Burow completed her Internal Medicine Residency in 2005 and her Hematology/Oncology Fellowship in 2008 both at Tulane University School of Medicine in New Orleans, Louisiana.
In July 2008, Dr. Collins-Burow joined Tulane University School of Medicine, Department of Medicine, Section of Hematology/Oncology as an Assistant Professor of Medicine.
Dr. Collins-Burow's research program combines investigator initiated proof-of principle clinical trials with solid basic-translational bench research. Dr. Collins-Burow’s research focuses on the role of novel experimental agents and epigenetic therapy in the regulation of microRNA expression in breast cancer with specific interest in triple-negative or basal phenotype breast cancer.
Tilghman SL, Zimmermann, MC, Boué SM, Salvo V.A, Elliott S, Williams K.Y, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MS, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME. Glyceollin I, a novel anti-estrogenic phytoalexin isolated from activated soy. Journal Pharmacology & Experimental Therapeutics 2009. Accepted for publication.
Collins-Burow BM. Lymphadenopathy and Splenomegaly. Medicine: A Competency-Based Companion. JL Israel and AR Tunkel (Eds.) Elsevier, 2008.
Collins-Burow BM, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev. Anticancer Ther. 2007; 7(3): 257-273.
Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt P, Beckman BS, McLachlan JA, Cleveland TE, Burow ME. Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis. Clinical Cancer Research 2006; 12(23): 7159-7164.
Frigo DE, Basu A, Simpson EN, Weldon CB, Elliott S, Melnik LI, Dugan CB, Collins-Burow BM, Zhu Y, Salvo VA, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME. The p38 MAPK Stimulates Estrogen-Mediated Transcription and Proliferation through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid Receptor-Interacting Protein 1. Molecular Endocrinology 2006; 20(5): 971-983.
Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS. PKC-mediated Survival signaling in Breast carcinoma cells: a role for MEK1-AP1 signaling. International Journal of Oncology2005; 26(3): 763-768.
Collins-Burow BM, Burow ME, Duong BN, McLachlan JA. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutrition and Cancer 2000; 38(2), 229-244.
Burow ME, Tang Y, Collins-Burow BM, Krajewski, S, Reed,JC, McLachlan JA, Beckman, BS. Effects of environmental estrogens on TNF-mediated apoptosis in MCF-7 breast carcinoma cells. Carcinogenesis 1999; 20(11): 2057-2061.
Collins BM, McLachlan JA, Arnold SF. The estrogenic and antiestrogenic activities of various phytochemicals with the human estrogen receptor expressed in yeast. Steroids 1997; 63:364-371.
To view more of Dr. Collins-Burow's publications, visit PubMed.
